Project factsheets

Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes

Antimicrobial Resistance Accelerator

Amyloid imaging to prevent Alzheimer’s disease

conect4children - Collaborative network for European clinical trials for children

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

Combatting bacterial resistance in Europe - molecules against Gram negative infections

Collaboration for prevention and treatment of MDR bacterial infections

Electronic Health Records Systems for Clinical Research

European prevention of Alzheimer’s dementia consortium

European Autism Interventions - a Multicentre Study for Developing New Medications

EU patient-centric clinical trial platform

Understanding chronic pain and improving its treatment

Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem

Incorporating real-life clinical data into drug development

Inhaled antibiotics in bronchiectasis and cystic fibrosis

Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes.

Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA

New clinical endpoints in primary Sjögren’s syndrome: an interventional trial based on stratifying patients

Novel methods leading to new medications in depression and schizophrenia

Patients active in research and dialogues for an improved generation of medicines: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development

Model-based preclinical development of anti-tuberculosis drug combinations

Patient Preferences in benefit risk assessments during the drug life cycle

Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD

Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification

Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials

Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools

Center of excellence – remote decentralised clinical trials

Academia and industry united innovation and treatment for tuberculosis